A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer

Abstract Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer. T-VEC was injected intratumor...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Megumi Kai, Angela N. Marx, Diane D. Liu, Yu Shen, Hui Gao, James M. Reuben, Gary Whitman, Savitri Krishnamurthy, Merrick I. Ross, Jennifer K. Litton, Bora Lim, Nuhad Ibrahim, Takahiro Kogawa, Naoto T. Ueno
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/c37b0ab005ba4205ac526ecb4d11aff8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/c37b0ab005ba4205ac526ecb4d11aff8

Ejemplares similares